| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholestasis | 59 | 2023 | 228 | 13.020 |
Why?
|
| Biliary Atresia | 58 | 2024 | 224 | 9.260 |
Why?
|
| Liver Diseases | 44 | 2022 | 282 | 8.660 |
Why?
|
| Parenteral Nutrition | 16 | 2023 | 92 | 6.220 |
Why?
|
| Liver | 62 | 2023 | 1816 | 4.040 |
Why?
|
| Bile Acids and Salts | 24 | 2023 | 179 | 3.790 |
Why?
|
| Hypertension, Portal | 15 | 2023 | 67 | 3.510 |
Why?
|
| Vitamin E | 50 | 2016 | 116 | 3.240 |
Why?
|
| Alagille Syndrome | 13 | 2024 | 37 | 2.910 |
Why?
|
| Vitamin E Deficiency | 36 | 2016 | 42 | 2.750 |
Why?
|
| Hepatopulmonary Syndrome | 6 | 2018 | 26 | 2.730 |
Why?
|
| Bilirubin | 24 | 2023 | 95 | 2.700 |
Why?
|
| Liver Transplantation | 41 | 2023 | 847 | 2.630 |
Why?
|
| Mitochondria, Liver | 19 | 2013 | 70 | 2.590 |
Why?
|
| Intestinal Diseases | 5 | 2021 | 30 | 2.560 |
Why?
|
| Cholestasis, Intrahepatic | 15 | 2023 | 43 | 2.530 |
Why?
|
| Hepatocytes | 13 | 2023 | 205 | 2.230 |
Why?
|
| Antioxidants | 16 | 2023 | 564 | 2.100 |
Why?
|
| Liver Failure, Acute | 10 | 2023 | 63 | 2.030 |
Why?
|
| Infant | 128 | 2023 | 8295 | 1.950 |
Why?
|
| Portoenterostomy, Hepatic | 18 | 2023 | 64 | 1.790 |
Why?
|
| Mitochondrial Diseases | 8 | 2024 | 79 | 1.720 |
Why?
|
| Infant, Newborn | 71 | 2023 | 5256 | 1.660 |
Why?
|
| Fat Emulsions, Intravenous | 3 | 2020 | 31 | 1.620 |
Why?
|
| Neonatal Screening | 12 | 2019 | 152 | 1.620 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2021 | 195 | 1.590 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2021 | 106 | 1.450 |
Why?
|
| Child | 131 | 2024 | 19137 | 1.450 |
Why?
|
| Humans | 271 | 2024 | 119032 | 1.330 |
Why?
|
| Hypertension, Pulmonary | 9 | 2018 | 1794 | 1.330 |
Why?
|
| Phytosterols | 2 | 2021 | 9 | 1.290 |
Why?
|
| NF-kappa B | 3 | 2023 | 670 | 1.260 |
Why?
|
| Glycochenodeoxycholic Acid | 9 | 2008 | 12 | 1.250 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 7 | 2024 | 280 | 1.240 |
Why?
|
| Cystic Fibrosis | 20 | 2016 | 965 | 1.220 |
Why?
|
| Lipoproteins | 5 | 2021 | 163 | 1.140 |
Why?
|
| Gastroenterology | 5 | 2016 | 158 | 1.110 |
Why?
|
| Kupffer Cells | 5 | 2020 | 47 | 1.070 |
Why?
|
| Fatty Liver | 7 | 2020 | 253 | 1.060 |
Why?
|
| Child, Preschool | 93 | 2022 | 9493 | 0.990 |
Why?
|
| Male | 150 | 2023 | 57818 | 0.950 |
Why?
|
| Liver Cirrhosis | 11 | 2023 | 245 | 0.940 |
Why?
|
| Bile Ducts | 10 | 2014 | 73 | 0.930 |
Why?
|
| Animals | 61 | 2023 | 33399 | 0.890 |
Why?
|
| Cholagogues and Choleretics | 2 | 2019 | 10 | 0.860 |
Why?
|
| Intestines | 4 | 2015 | 332 | 0.840 |
Why?
|
| Abdominal Injuries | 1 | 2023 | 119 | 0.840 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 75 | 0.840 |
Why?
|
| Oxidative Stress | 12 | 2018 | 1179 | 0.830 |
Why?
|
| Isoxazoles | 1 | 2021 | 56 | 0.810 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2019 | 91 | 0.790 |
Why?
|
| Mice | 19 | 2023 | 15528 | 0.770 |
Why?
|
| Short Bowel Syndrome | 2 | 2020 | 19 | 0.770 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2023 | 1175 | 0.750 |
Why?
|
| Dietary Supplements | 7 | 2022 | 467 | 0.720 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 379 | 0.710 |
Why?
|
| Interleukin-6 | 2 | 2023 | 692 | 0.700 |
Why?
|
| Copper | 11 | 1998 | 102 | 0.700 |
Why?
|
| Nutritional Support | 1 | 2019 | 28 | 0.690 |
Why?
|
| Research | 6 | 2007 | 411 | 0.690 |
Why?
|
| Bile | 2 | 2016 | 31 | 0.680 |
Why?
|
| Disease Models, Animal | 13 | 2023 | 3730 | 0.670 |
Why?
|
| Female | 131 | 2023 | 61588 | 0.670 |
Why?
|
| Gastrointestinal Diseases | 5 | 2007 | 187 | 0.650 |
Why?
|
| Macrophages | 6 | 2021 | 1324 | 0.650 |
Why?
|
| Hypoxia | 5 | 2018 | 963 | 0.650 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 95 | 0.650 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 30 | 0.640 |
Why?
|
| Macrophage Activation | 5 | 2023 | 168 | 0.640 |
Why?
|
| Adolescent | 68 | 2022 | 18483 | 0.640 |
Why?
|
| Apoptosis | 10 | 2007 | 2484 | 0.620 |
Why?
|
| Reactive Oxygen Species | 8 | 2005 | 576 | 0.620 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2018 | 57 | 0.610 |
Why?
|
| Gene Expression | 3 | 2021 | 1492 | 0.610 |
Why?
|
| Rats | 28 | 2011 | 5394 | 0.590 |
Why?
|
| Hepatitis, Viral, Human | 4 | 2012 | 26 | 0.590 |
Why?
|
| Lipid Peroxidation | 11 | 1998 | 156 | 0.590 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 234 | 0.580 |
Why?
|
| DNA, Mitochondrial | 7 | 2023 | 187 | 0.580 |
Why?
|
| Vitamin A Deficiency | 4 | 2005 | 26 | 0.580 |
Why?
|
| Liver Failure | 6 | 2011 | 85 | 0.570 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 4 | 2023 | 79 | 0.560 |
Why?
|
| Hepatitis B | 3 | 2009 | 52 | 0.550 |
Why?
|
| Sarcopenia | 3 | 2023 | 72 | 0.540 |
Why?
|
| End Stage Liver Disease | 1 | 2017 | 73 | 0.530 |
Why?
|
| Severity of Illness Index | 10 | 2022 | 2674 | 0.520 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2661 | 0.520 |
Why?
|
| Cytomegalovirus Infections | 4 | 2024 | 187 | 0.520 |
Why?
|
| Nervous System Diseases | 10 | 2001 | 261 | 0.510 |
Why?
|
| Vitamins | 7 | 2022 | 159 | 0.500 |
Why?
|
| alpha-Tocopherol | 4 | 2012 | 24 | 0.500 |
Why?
|
| Preoperative Care | 1 | 2017 | 332 | 0.490 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2014 | 6 | 0.490 |
Why?
|
| Mitochondria | 9 | 2013 | 786 | 0.480 |
Why?
|
| Nutritional Status | 10 | 2021 | 300 | 0.470 |
Why?
|
| Pruritus | 5 | 2023 | 60 | 0.460 |
Why?
|
| Health Status | 5 | 2015 | 726 | 0.450 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 3 | 2008 | 31 | 0.450 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2010 | 18 | 0.450 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2013 | 330 | 0.440 |
Why?
|
| Prospective Studies | 26 | 2022 | 6477 | 0.430 |
Why?
|
| Vitamin D | 6 | 2014 | 354 | 0.420 |
Why?
|
| Vitamin A | 6 | 2014 | 55 | 0.420 |
Why?
|
| Metabolism, Inborn Errors | 4 | 2008 | 38 | 0.420 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2022 | 44 | 0.420 |
Why?
|
| Pediatrics | 5 | 2013 | 985 | 0.420 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 117 | 0.420 |
Why?
|
| Quality of Life | 8 | 2023 | 2369 | 0.410 |
Why?
|
| Prognosis | 14 | 2023 | 3443 | 0.410 |
Why?
|
| Rare Diseases | 3 | 2022 | 113 | 0.410 |
Why?
|
| Intestinal Absorption | 7 | 1994 | 104 | 0.410 |
Why?
|
| Aspartate Aminotransferases | 8 | 2022 | 95 | 0.400 |
Why?
|
| Parenteral Nutrition, Total | 6 | 2004 | 39 | 0.400 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2015 | 548 | 0.400 |
Why?
|
| Treatment Outcome | 26 | 2023 | 9346 | 0.400 |
Why?
|
| Mutation | 13 | 2021 | 3457 | 0.400 |
Why?
|
| Abnormalities, Multiple | 6 | 2019 | 182 | 0.400 |
Why?
|
| gamma-Glutamyltransferase | 6 | 2020 | 43 | 0.400 |
Why?
|
| Microsomes, Liver | 4 | 2004 | 59 | 0.390 |
Why?
|
| Glutathione | 6 | 2006 | 324 | 0.390 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2006 | 2478 | 0.390 |
Why?
|
| Ubiquinone | 3 | 2008 | 25 | 0.390 |
Why?
|
| Prevalence | 11 | 2020 | 2326 | 0.380 |
Why?
|
| Alanine Transaminase | 8 | 2016 | 152 | 0.380 |
Why?
|
| Biomarkers | 15 | 2024 | 3590 | 0.370 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2021 | 36 | 0.370 |
Why?
|
| F2-Isoprostanes | 3 | 2018 | 17 | 0.370 |
Why?
|
| Microbiota | 2 | 2014 | 656 | 0.370 |
Why?
|
| Natriuretic Peptides | 1 | 2009 | 8 | 0.360 |
Why?
|
| Cell Membrane Permeability | 3 | 2012 | 88 | 0.360 |
Why?
|
| Hepatolenticular Degeneration | 4 | 1996 | 18 | 0.360 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 4914 | 0.360 |
Why?
|
| Chronic Disease | 16 | 2018 | 1637 | 0.360 |
Why?
|
| Survival Rate | 11 | 2017 | 1720 | 0.350 |
Why?
|
| Vitamin D Deficiency | 4 | 2011 | 162 | 0.350 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 2446 | 0.350 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2019 | 128 | 0.350 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2009 | 10 | 0.350 |
Why?
|
| Roseolovirus Infections | 1 | 2009 | 6 | 0.350 |
Why?
|
| Cohort Studies | 14 | 2022 | 5117 | 0.340 |
Why?
|
| Aldehydes | 2 | 2022 | 154 | 0.340 |
Why?
|
| Cytochromes c | 5 | 2008 | 64 | 0.340 |
Why?
|
| Agammaglobulinemia | 1 | 2009 | 32 | 0.330 |
Why?
|
| Glycyrrhetinic Acid | 2 | 2006 | 7 | 0.330 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2010 | 125 | 0.330 |
Why?
|
| Mitochondrial Membranes | 1 | 2008 | 34 | 0.330 |
Why?
|
| Signal Transduction | 6 | 2023 | 4713 | 0.330 |
Why?
|
| Hirschsprung Disease | 1 | 2010 | 89 | 0.320 |
Why?
|
| Time Factors | 17 | 2018 | 6414 | 0.320 |
Why?
|
| Malabsorption Syndromes | 5 | 2020 | 15 | 0.320 |
Why?
|
| Intussusception | 1 | 2007 | 27 | 0.310 |
Why?
|
| Survivors | 5 | 2014 | 418 | 0.310 |
Why?
|
| beta Carotene | 4 | 2007 | 17 | 0.310 |
Why?
|
| Colonic Diseases | 1 | 2007 | 26 | 0.310 |
Why?
|
| Genes, Mitochondrial | 1 | 2007 | 14 | 0.310 |
Why?
|
| Autoantibodies | 7 | 2006 | 1335 | 0.310 |
Why?
|
| Taurochenodeoxycholic Acid | 4 | 2005 | 7 | 0.300 |
Why?
|
| Membrane Proteins | 4 | 2019 | 1056 | 0.300 |
Why?
|
| Hepatitis | 4 | 2020 | 46 | 0.300 |
Why?
|
| Inflammation | 7 | 2023 | 2571 | 0.300 |
Why?
|
| Immunity, Innate | 1 | 2013 | 745 | 0.300 |
Why?
|
| Antiviral Agents | 3 | 2009 | 654 | 0.300 |
Why?
|
| Abdomen, Acute | 1 | 2006 | 20 | 0.290 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 17 | 0.290 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 2011 | 27 | 0.280 |
Why?
|
| Colonic Polyps | 1 | 2007 | 70 | 0.280 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 4596 | 0.280 |
Why?
|
| Influenza A virus | 1 | 2006 | 91 | 0.280 |
Why?
|
| Necrosis | 6 | 2005 | 231 | 0.280 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 1998 | 136 | 0.270 |
Why?
|
| Growth Disorders | 3 | 2018 | 77 | 0.270 |
Why?
|
| Child Welfare | 3 | 2020 | 199 | 0.270 |
Why?
|
| Galactose | 2 | 2003 | 20 | 0.270 |
Why?
|
| Prothrombin Time | 5 | 2012 | 35 | 0.260 |
Why?
|
| Glycyrrhizic Acid | 1 | 2005 | 3 | 0.260 |
Why?
|
| Glycyrrhiza | 1 | 2005 | 2 | 0.260 |
Why?
|
| Caspases | 3 | 2018 | 269 | 0.260 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2011 | 27 | 0.260 |
Why?
|
| Interferon-alpha | 3 | 2009 | 191 | 0.260 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2021 | 135 | 0.260 |
Why?
|
| Oxidants | 2 | 1996 | 122 | 0.250 |
Why?
|
| Ion Channels | 2 | 2005 | 126 | 0.250 |
Why?
|
| Enzyme Inhibitors | 4 | 2005 | 829 | 0.250 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2006 | 176 | 0.250 |
Why?
|
| Cyclosporine | 2 | 2005 | 173 | 0.250 |
Why?
|
| Diagnosis, Differential | 6 | 2017 | 1384 | 0.250 |
Why?
|
| Retrospective Studies | 17 | 2023 | 12990 | 0.250 |
Why?
|
| Autoimmunity | 5 | 2013 | 831 | 0.240 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2022 | 40 | 0.240 |
Why?
|
| Facies | 1 | 2004 | 22 | 0.240 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2012 | 115 | 0.240 |
Why?
|
| Celiac Disease | 5 | 2006 | 267 | 0.240 |
Why?
|
| Ursodeoxycholic Acid | 3 | 2015 | 22 | 0.240 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 968 | 0.240 |
Why?
|
| Avitaminosis | 2 | 2014 | 7 | 0.240 |
Why?
|
| Fetal Diseases | 1 | 2005 | 148 | 0.240 |
Why?
|
| Metabolic Diseases | 2 | 2014 | 103 | 0.240 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2024 | 35 | 0.240 |
Why?
|
| Phenotype | 9 | 2023 | 3004 | 0.230 |
Why?
|
| Genes, Regulator | 1 | 2023 | 33 | 0.230 |
Why?
|
| ARNTL Transcription Factors | 1 | 2023 | 16 | 0.230 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 788 | 0.230 |
Why?
|
| Erythrocytes | 4 | 2001 | 641 | 0.230 |
Why?
|
| Waiting Lists | 3 | 2017 | 228 | 0.230 |
Why?
|
| alpha 1-Antitrypsin | 3 | 2023 | 115 | 0.230 |
Why?
|
| Glucocorticoids | 1 | 2007 | 547 | 0.230 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2023 | 8 | 0.230 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 60 | 0.230 |
Why?
|
| Enterohepatic Circulation | 2 | 2017 | 8 | 0.220 |
Why?
|
| Serum Albumin | 5 | 2012 | 147 | 0.220 |
Why?
|
| Early Diagnosis | 2 | 2019 | 230 | 0.220 |
Why?
|
| Biliary Tract Diseases | 2 | 2002 | 35 | 0.220 |
Why?
|
| Sterols | 2 | 2021 | 17 | 0.220 |
Why?
|
| Lipids | 10 | 2013 | 608 | 0.220 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 521 | 0.220 |
Why?
|
| Adult | 40 | 2022 | 31525 | 0.220 |
Why?
|
| Europe | 4 | 2016 | 356 | 0.220 |
Why?
|
| Exocrine Pancreatic Insufficiency | 3 | 2012 | 17 | 0.210 |
Why?
|
| Abdominal Pain | 2 | 2007 | 134 | 0.210 |
Why?
|
| Varicose Veins | 1 | 2022 | 15 | 0.210 |
Why?
|
| Benzimidazoles | 1 | 2023 | 140 | 0.210 |
Why?
|
| United States | 20 | 2020 | 12557 | 0.210 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 31 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 3 | 2016 | 288 | 0.210 |
Why?
|
| Jaundice, Neonatal | 3 | 1987 | 8 | 0.200 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 150 | 0.200 |
Why?
|
| Hepatic Encephalopathy | 2 | 1998 | 22 | 0.200 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 79 | 0.200 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 73 | 0.200 |
Why?
|
| Reference Values | 6 | 2018 | 775 | 0.200 |
Why?
|
| Infliximab | 1 | 2021 | 94 | 0.200 |
Why?
|
| Bongkrekic Acid | 1 | 2001 | 2 | 0.200 |
Why?
|
| Feces | 2 | 2015 | 396 | 0.200 |
Why?
|
| Lung | 3 | 2012 | 3666 | 0.200 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2021 | 135 | 0.200 |
Why?
|
| Pilot Projects | 6 | 2018 | 1420 | 0.200 |
Why?
|
| Anemia, Hemolytic | 1 | 2001 | 19 | 0.200 |
Why?
|
| Biopsy | 12 | 2017 | 1079 | 0.200 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2013 | 290 | 0.190 |
Why?
|
| Malnutrition | 1 | 2021 | 66 | 0.190 |
Why?
|
| Longitudinal Studies | 9 | 2021 | 2513 | 0.190 |
Why?
|
| Vitamin K | 4 | 2014 | 44 | 0.190 |
Why?
|
| Influenza, Human | 2 | 2006 | 555 | 0.190 |
Why?
|
| Fontan Procedure | 1 | 2003 | 154 | 0.190 |
Why?
|
| Risk Factors | 10 | 2020 | 9003 | 0.190 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 564 | 0.190 |
Why?
|
| Hepatoblastoma | 1 | 2000 | 27 | 0.190 |
Why?
|
| Creativity | 1 | 2020 | 8 | 0.190 |
Why?
|
| Cytochrome-c Oxidase Deficiency | 1 | 2020 | 3 | 0.190 |
Why?
|
| Adenosine Triphosphatases | 1 | 2021 | 158 | 0.190 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 311 | 0.190 |
Why?
|
| Soybean Oil | 1 | 2020 | 12 | 0.190 |
Why?
|
| Age Factors | 8 | 2017 | 2995 | 0.190 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 421 | 0.180 |
Why?
|
| Survival Analysis | 7 | 2021 | 1267 | 0.180 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 60 | 0.180 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 1990 | 122 | 0.180 |
Why?
|
| Emulsions | 2 | 2013 | 45 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2020 | 57 | 0.180 |
Why?
|
| Liver Function Tests | 8 | 2016 | 107 | 0.180 |
Why?
|
| Colitis, Ulcerative | 3 | 2010 | 105 | 0.180 |
Why?
|
| Hydrogen Peroxide | 2 | 2005 | 305 | 0.180 |
Why?
|
| Outpatients | 1 | 2022 | 325 | 0.180 |
Why?
|
| Immunoblotting | 4 | 2014 | 307 | 0.180 |
Why?
|
| Ascites | 2 | 2015 | 37 | 0.170 |
Why?
|
| Registries | 6 | 2017 | 1810 | 0.170 |
Why?
|
| Fibroblasts | 3 | 2014 | 843 | 0.170 |
Why?
|
| Hypersplenism | 1 | 1998 | 7 | 0.170 |
Why?
|
| Societies, Medical | 3 | 2016 | 703 | 0.170 |
Why?
|
| Autophagy | 1 | 2022 | 315 | 0.170 |
Why?
|
| Rotavirus Infections | 3 | 2006 | 54 | 0.170 |
Why?
|
| Oxypurinol | 1 | 1998 | 1 | 0.170 |
Why?
|
| Syndrome | 6 | 2019 | 344 | 0.170 |
Why?
|
| Disease Progression | 4 | 2020 | 2490 | 0.170 |
Why?
|
| Zinc | 2 | 1999 | 262 | 0.170 |
Why?
|
| Failure to Thrive | 1 | 2018 | 31 | 0.170 |
Why?
|
| Vertebrates | 1 | 1999 | 59 | 0.160 |
Why?
|
| Dystroglycans | 1 | 2018 | 7 | 0.160 |
Why?
|
| Qb-SNARE Proteins | 1 | 2018 | 6 | 0.160 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2019 | 55 | 0.160 |
Why?
|
| Polyethylene Glycols | 8 | 2012 | 578 | 0.160 |
Why?
|
| Research Design | 2 | 2016 | 969 | 0.160 |
Why?
|
| Caspases, Initiator | 1 | 2018 | 18 | 0.160 |
Why?
|
| Liver X Receptors | 1 | 2018 | 30 | 0.160 |
Why?
|
| Xanthine Oxidase | 1 | 1998 | 80 | 0.160 |
Why?
|
| North America | 5 | 2016 | 266 | 0.160 |
Why?
|
| Cytomegalovirus | 2 | 2023 | 144 | 0.160 |
Why?
|
| Safety | 1 | 2020 | 304 | 0.160 |
Why?
|
| Benzoquinones | 1 | 1998 | 44 | 0.160 |
Why?
|
| Calcifediol | 2 | 2011 | 29 | 0.160 |
Why?
|
| Muscular Dystrophies | 1 | 2018 | 36 | 0.160 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2020 | 116 | 0.160 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 1691 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 1998 | 126 | 0.160 |
Why?
|
| Morphogenesis | 1 | 1999 | 167 | 0.160 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 539 | 0.160 |
Why?
|
| Premature Birth | 1 | 2021 | 284 | 0.160 |
Why?
|
| Intestine, Small | 3 | 2005 | 131 | 0.160 |
Why?
|
| Fructose | 2 | 2022 | 204 | 0.160 |
Why?
|
| Cross-Sectional Studies | 7 | 2013 | 4552 | 0.160 |
Why?
|
| Injections, Subcutaneous | 3 | 2007 | 139 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 1998 | 73 | 0.150 |
Why?
|
| Fibrosis | 3 | 2014 | 483 | 0.150 |
Why?
|
| Virus Diseases | 3 | 2013 | 198 | 0.150 |
Why?
|
| Oximetry | 1 | 2018 | 84 | 0.150 |
Why?
|
| Caspase 1 | 1 | 2018 | 143 | 0.150 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 84 | 0.150 |
Why?
|
| Indians, North American | 2 | 2001 | 598 | 0.150 |
Why?
|
| Emotional Adjustment | 1 | 2017 | 18 | 0.150 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2018 | 228 | 0.150 |
Why?
|
| Spleen | 1 | 2019 | 510 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 254 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2005 | 369 | 0.150 |
Why?
|
| Obesity | 3 | 2013 | 2751 | 0.150 |
Why?
|
| Graft Survival | 3 | 2012 | 504 | 0.150 |
Why?
|
| Ammonia | 2 | 2008 | 65 | 0.150 |
Why?
|
| Schools | 1 | 2020 | 411 | 0.150 |
Why?
|
| Embolization, Therapeutic | 1 | 1998 | 192 | 0.140 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 48 | 0.140 |
Why?
|
| Rats, Zucker | 2 | 2007 | 34 | 0.140 |
Why?
|
| Nitric Oxide | 1 | 2002 | 893 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2007 | 170 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 527 | 0.140 |
Why?
|
| Trans-Activators | 1 | 1999 | 373 | 0.140 |
Why?
|
| Family Relations | 1 | 2017 | 85 | 0.140 |
Why?
|
| Lactic Acid | 2 | 2017 | 282 | 0.140 |
Why?
|
| Body Mass Index | 4 | 2018 | 2092 | 0.140 |
Why?
|
| History, 20th Century | 2 | 2007 | 281 | 0.140 |
Why?
|
| Hepatitis, Chronic | 1 | 1995 | 5 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2021 | 53 | 0.140 |
Why?
|
| Cell Death | 2 | 2008 | 339 | 0.140 |
Why?
|
| Flow Cytometry | 3 | 2005 | 1085 | 0.140 |
Why?
|
| Oxidative Phosphorylation | 4 | 2003 | 156 | 0.130 |
Why?
|
| Cholesterol | 7 | 2015 | 375 | 0.130 |
Why?
|
| Predictive Value of Tests | 6 | 2014 | 1868 | 0.130 |
Why?
|
| Rotavirus | 4 | 2014 | 26 | 0.130 |
Why?
|
| Incidence | 7 | 2013 | 2424 | 0.130 |
Why?
|
| Metals | 1 | 1996 | 111 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2021 | 637 | 0.130 |
Why?
|
| Bone Density | 1 | 2018 | 449 | 0.130 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1995 | 14 | 0.130 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 247 | 0.130 |
Why?
|
| Skinfold Thickness | 2 | 2012 | 46 | 0.130 |
Why?
|
| Echocardiography | 2 | 2009 | 556 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 2275 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 1995 | 35 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
|
| Plant Oils | 1 | 2014 | 28 | 0.130 |
Why?
|
| Neuromuscular Diseases | 2 | 1989 | 90 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2016 | 174 | 0.130 |
Why?
|
| Free Radicals | 4 | 1998 | 104 | 0.120 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 190 | 0.120 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hydrogen | 1 | 2014 | 65 | 0.120 |
Why?
|
| Oxygen Consumption | 3 | 1995 | 586 | 0.120 |
Why?
|
| Prednisolone | 1 | 2014 | 76 | 0.120 |
Why?
|
| Stigmasterol | 1 | 2013 | 2 | 0.120 |
Why?
|
| Solutions | 2 | 2013 | 156 | 0.120 |
Why?
|
| Portal Vein | 2 | 2010 | 90 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2007 | 439 | 0.120 |
Why?
|
| Administration, Oral | 4 | 2014 | 756 | 0.120 |
Why?
|
| Bile Canaliculi | 1 | 2013 | 11 | 0.120 |
Why?
|
| Mental Health | 1 | 2009 | 568 | 0.120 |
Why?
|
| Methylprednisolone | 1 | 2014 | 84 | 0.120 |
Why?
|
| Forms and Records Control | 1 | 2013 | 23 | 0.120 |
Why?
|
| Oxidation-Reduction | 3 | 2008 | 940 | 0.120 |
Why?
|
| Fish Oils | 1 | 2013 | 25 | 0.120 |
Why?
|
| Random Allocation | 2 | 2012 | 349 | 0.120 |
Why?
|
| Gastritis, Hypertrophic | 1 | 1993 | 3 | 0.120 |
Why?
|
| Membrane Potentials | 2 | 2005 | 253 | 0.120 |
Why?
|
| Health Policy | 1 | 2017 | 333 | 0.120 |
Why?
|
| Oxygen | 2 | 2001 | 857 | 0.120 |
Why?
|
| Tight Junctions | 1 | 2014 | 69 | 0.120 |
Why?
|
| Bile Ducts, Extrahepatic | 3 | 2007 | 28 | 0.120 |
Why?
|
| Electron Transport Complex IV | 1 | 1993 | 53 | 0.120 |
Why?
|
| Acidosis, Lactic | 1 | 2013 | 29 | 0.110 |
Why?
|
| Mass Screening | 3 | 2018 | 1052 | 0.110 |
Why?
|
| Dietary Fats | 3 | 1993 | 325 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2005 | 243 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2021 | 125 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2022 | 109 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2005 | 1947 | 0.110 |
Why?
|
| Caspase 9 | 2 | 2005 | 50 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 1032 | 0.110 |
Why?
|
| Prune Belly Syndrome | 1 | 1993 | 9 | 0.110 |
Why?
|
| Autoimmune Diseases | 3 | 2005 | 398 | 0.110 |
Why?
|
| Laparoscopy | 1 | 1997 | 418 | 0.110 |
Why?
|
| Pregnancy | 7 | 2021 | 5694 | 0.110 |
Why?
|
| Caspase Inhibitors | 2 | 2005 | 82 | 0.110 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 3 | 1998 | 22 | 0.110 |
Why?
|
| Histocytochemistry | 2 | 2011 | 82 | 0.110 |
Why?
|
| Pancreatic Elastase | 1 | 2012 | 74 | 0.110 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2006 | 111 | 0.110 |
Why?
|
| Abetalipoproteinemia | 2 | 1996 | 3 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 137 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 273 | 0.110 |
Why?
|
| Nutrition Assessment | 2 | 2004 | 78 | 0.110 |
Why?
|
| Epithelium | 2 | 2006 | 305 | 0.110 |
Why?
|
| Nutrition Disorders | 2 | 1998 | 23 | 0.110 |
Why?
|
| Serrate-Jagged Proteins | 2 | 2004 | 30 | 0.100 |
Why?
|
| ROC Curve | 2 | 2015 | 473 | 0.100 |
Why?
|
| Cerebral Palsy | 1 | 2013 | 80 | 0.100 |
Why?
|
| Case-Control Studies | 7 | 2015 | 3173 | 0.100 |
Why?
|
| Financing, Organized | 2 | 2002 | 34 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1355 | 0.100 |
Why?
|
| Cyclosporins | 1 | 1991 | 60 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2018 | 984 | 0.100 |
Why?
|
| Databases, Factual | 4 | 2019 | 1231 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2021 | 3057 | 0.100 |
Why?
|
| Young Adult | 8 | 2021 | 10799 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 175 | 0.100 |
Why?
|
| Pedigree | 5 | 2014 | 485 | 0.100 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2010 | 4 | 0.100 |
Why?
|
| Wechsler Scales | 2 | 2022 | 57 | 0.100 |
Why?
|
| Diet | 3 | 2011 | 1155 | 0.100 |
Why?
|
| Retinol-Binding Proteins | 2 | 2012 | 13 | 0.100 |
Why?
|
| Anthropometry | 2 | 1992 | 194 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 70 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1687 | 0.100 |
Why?
|
| Heterotaxy Syndrome | 1 | 2010 | 9 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 781 | 0.090 |
Why?
|
| Proteins | 3 | 2004 | 938 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2008 | 683 | 0.090 |
Why?
|
| Steroid Metabolism, Inborn Errors | 1 | 2010 | 1 | 0.090 |
Why?
|
| Colorado | 6 | 2013 | 4196 | 0.090 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2010 | 9 | 0.090 |
Why?
|
| Transglutaminases | 4 | 2006 | 143 | 0.090 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 394 | 0.090 |
Why?
|
| Global Health | 1 | 2012 | 310 | 0.090 |
Why?
|
| Manganese | 3 | 1998 | 55 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 2 | 2004 | 217 | 0.090 |
Why?
|
| Adoption | 1 | 1990 | 38 | 0.090 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 531 | 0.090 |
Why?
|
| Genotype | 2 | 2013 | 1882 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 985 | 0.090 |
Why?
|
| Membrane Lipids | 1 | 1990 | 88 | 0.090 |
Why?
|
| Hemochromatosis | 1 | 2009 | 9 | 0.090 |
Why?
|
| Carotenoids | 3 | 2007 | 35 | 0.090 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2009 | 18 | 0.090 |
Why?
|
| Animals, Newborn | 4 | 2014 | 806 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 2 | 1989 | 210 | 0.090 |
Why?
|
| Electron Transport | 4 | 1999 | 101 | 0.090 |
Why?
|
| Chenodeoxycholic Acid | 2 | 2021 | 12 | 0.090 |
Why?
|
| Herpesvirus 7, Human | 1 | 2009 | 5 | 0.090 |
Why?
|
| Galactosemias | 1 | 1989 | 8 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2003 | 2179 | 0.090 |
Why?
|
| Canada | 4 | 2015 | 340 | 0.080 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 1989 | 23 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2011 | 3361 | 0.080 |
Why?
|
| Cell Survival | 4 | 1996 | 1047 | 0.080 |
Why?
|
| Lamivudine | 1 | 2009 | 59 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2010 | 341 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2014 | 702 | 0.080 |
Why?
|
| Blood Transfusion | 2 | 1989 | 306 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2019 | 815 | 0.080 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2008 | 18 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2008 | 490 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 870 | 0.080 |
Why?
|
| Organophosphonates | 1 | 2009 | 94 | 0.080 |
Why?
|
| Tocopherols | 3 | 2005 | 20 | 0.080 |
Why?
|
| Cardiolipins | 1 | 2008 | 73 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2014 | 737 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 1774 | 0.080 |
Why?
|
| Sural Nerve | 3 | 1987 | 20 | 0.080 |
Why?
|
| Crohn Disease | 2 | 1997 | 197 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2006 | 542 | 0.080 |
Why?
|
| Lipid Metabolism | 2 | 1988 | 477 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 1440 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 1474 | 0.080 |
Why?
|
| Educational Status | 2 | 2020 | 437 | 0.080 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2007 | 19 | 0.080 |
Why?
|
| Selection Bias | 1 | 2007 | 35 | 0.080 |
Why?
|
| Texas | 1 | 2007 | 186 | 0.070 |
Why?
|
| Adenine | 1 | 2009 | 223 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 225 | 0.070 |
Why?
|
| Rupture, Spontaneous | 1 | 2006 | 18 | 0.070 |
Why?
|
| Organizational Policy | 1 | 2007 | 70 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2005 | 311 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 92 | 0.070 |
Why?
|
| Th1 Cells | 2 | 2005 | 133 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2009 | 356 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2013 | 830 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 2025 | 0.070 |
Why?
|
| Logistic Models | 3 | 2017 | 1901 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2021 | 2680 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 1990 | 290 | 0.070 |
Why?
|
| Radiography | 4 | 1998 | 861 | 0.070 |
Why?
|
| Executive Function | 1 | 2010 | 391 | 0.070 |
Why?
|
| Pulmonary Artery | 2 | 2010 | 1063 | 0.070 |
Why?
|
| Eating | 2 | 2022 | 369 | 0.070 |
Why?
|
| Micronutrients | 1 | 2007 | 79 | 0.070 |
Why?
|
| Drainage | 2 | 2019 | 158 | 0.070 |
Why?
|
| Graft Rejection | 3 | 2011 | 555 | 0.070 |
Why?
|
| Ultrasonography | 3 | 2015 | 716 | 0.070 |
Why?
|
| Interleukin-8 | 2 | 2022 | 249 | 0.070 |
Why?
|
| Osmolar Concentration | 2 | 2001 | 185 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 965 | 0.070 |
Why?
|
| Ascorbic Acid | 2 | 1997 | 120 | 0.070 |
Why?
|
| Glycoproteins | 2 | 1999 | 319 | 0.070 |
Why?
|
| Diterpenes | 1 | 2005 | 31 | 0.070 |
Why?
|
| Pneumonia | 1 | 2011 | 592 | 0.070 |
Why?
|
| Enterostomy | 2 | 2014 | 8 | 0.070 |
Why?
|
| Postoperative Complications | 4 | 2019 | 2235 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2005 | 52 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 55 | 0.070 |
Why?
|
| Risk | 3 | 2018 | 854 | 0.070 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2005 | 4 | 0.070 |
Why?
|
| 1,4-alpha-Glucan Branching Enzyme | 1 | 2005 | 4 | 0.070 |
Why?
|
| Dry Eye Syndromes | 1 | 2005 | 24 | 0.070 |
Why?
|
| Edible Grain | 1 | 2005 | 43 | 0.070 |
Why?
|
| Caspase 10 | 1 | 2005 | 5 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 2 | 2005 | 225 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 1795 | 0.070 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 24 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2011 | 739 | 0.060 |
Why?
|
| Cells, Cultured | 5 | 2014 | 4081 | 0.060 |
Why?
|
| Glutens | 1 | 2005 | 56 | 0.060 |
Why?
|
| Neutrophils | 1 | 2010 | 1233 | 0.060 |
Why?
|
| Faculty, Medical | 1 | 2007 | 252 | 0.060 |
Why?
|
| Pancrelipase | 2 | 1999 | 6 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 87 | 0.060 |
Why?
|
| Child Development | 2 | 2020 | 410 | 0.060 |
Why?
|
| Hepatitis B, Chronic | 1 | 2004 | 18 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 116 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 982 | 0.060 |
Why?
|
| Jaundice | 2 | 2015 | 15 | 0.060 |
Why?
|
| Statistics, Nonparametric | 3 | 2008 | 403 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 155 | 0.060 |
Why?
|
| Base Sequence | 7 | 2014 | 2160 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 171 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 1985 | 143 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2018 | 237 | 0.060 |
Why?
|
| Reoviridae | 2 | 1998 | 38 | 0.060 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1984 | 43 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 5 | 1998 | 1012 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2011 | 351 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2007 | 233 | 0.060 |
Why?
|
| Retinal Diseases | 1 | 1984 | 81 | 0.060 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2003 | 6 | 0.060 |
Why?
|
| Spinal Nerves | 1 | 1983 | 5 | 0.060 |
Why?
|
| Reoviridae Infections | 2 | 1998 | 55 | 0.060 |
Why?
|
| Alkaline Phosphatase | 2 | 1996 | 158 | 0.060 |
Why?
|
| Weaning | 2 | 1996 | 57 | 0.060 |
Why?
|
| Taurocholic Acid | 2 | 1995 | 34 | 0.060 |
Why?
|
| Molecular Sequence Data | 7 | 2014 | 2873 | 0.060 |
Why?
|
| Cytosol | 1 | 2004 | 221 | 0.060 |
Why?
|
| Albumins | 2 | 2014 | 100 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 196 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 1 | 1984 | 93 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 355 | 0.060 |
Why?
|
| Blood Coagulation Tests | 1 | 2003 | 58 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 412 | 0.060 |
Why?
|
| Microscopy, Electron | 3 | 2002 | 413 | 0.060 |
Why?
|
| Endoglin | 1 | 2022 | 21 | 0.060 |
Why?
|
| Spinal Cord Diseases | 1 | 1983 | 39 | 0.060 |
Why?
|
| Models, Biological | 2 | 2014 | 1715 | 0.060 |
Why?
|
| Anastomosis, Surgical | 2 | 2011 | 146 | 0.060 |
Why?
|
| Facial Expression | 1 | 1983 | 62 | 0.060 |
Why?
|
| Remission Induction | 2 | 2010 | 247 | 0.060 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 23 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 380 | 0.060 |
Why?
|
| Movement Disorders | 1 | 1983 | 45 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 554 | 0.060 |
Why?
|
| Niemann-Pick Diseases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Seasons | 1 | 2005 | 462 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 467 | 0.050 |
Why?
|
| Quinacrine | 1 | 1982 | 8 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 1295 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 3 | 2014 | 1206 | 0.050 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2021 | 16 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2004 | 828 | 0.050 |
Why?
|
| Ontario | 1 | 2011 | 109 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 1982 | 43 | 0.050 |
Why?
|
| Neurologic Examination | 3 | 1988 | 126 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 770 | 0.050 |
Why?
|
| Enteral Nutrition | 2 | 2021 | 172 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 642 | 0.050 |
Why?
|
| Age of Onset | 2 | 2002 | 467 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2005 | 580 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 501 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2005 | 299 | 0.050 |
Why?
|
| International Cooperation | 2 | 2015 | 177 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2022 | 157 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2005 | 541 | 0.050 |
Why?
|
| Codon, Nonsense | 1 | 2021 | 38 | 0.050 |
Why?
|
| Superoxides | 2 | 2010 | 221 | 0.050 |
Why?
|
| Colon | 2 | 2010 | 238 | 0.050 |
Why?
|
| Caspase 8 | 1 | 2001 | 47 | 0.050 |
Why?
|
| Detergents | 1 | 2001 | 44 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2007 | 612 | 0.050 |
Why?
|
| Ataxia | 2 | 1995 | 38 | 0.050 |
Why?
|
| Calpain | 1 | 2001 | 54 | 0.050 |
Why?
|
| Hemangioendothelioma | 1 | 2000 | 13 | 0.050 |
Why?
|
| Acute Disease | 2 | 1999 | 941 | 0.050 |
Why?
|
| Age Distribution | 1 | 2011 | 362 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 228 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2001 | 184 | 0.050 |
Why?
|
| Body Weight | 2 | 2018 | 934 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 297 | 0.050 |
Why?
|
| Glutathione Disulfide | 1 | 2000 | 29 | 0.050 |
Why?
|
| Middle Aged | 9 | 2007 | 27627 | 0.050 |
Why?
|
| Scalp Dermatoses | 1 | 1980 | 2 | 0.050 |
Why?
|
| Allostasis | 1 | 2020 | 14 | 0.050 |
Why?
|
| Cattle | 2 | 2014 | 979 | 0.050 |
Why?
|
| Cholic Acid | 2 | 1998 | 4 | 0.050 |
Why?
|
| Haemophilus Infections | 1 | 1980 | 31 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 1308 | 0.040 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cellulitis | 1 | 1980 | 47 | 0.040 |
Why?
|
| Southwestern United States | 1 | 1999 | 94 | 0.040 |
Why?
|
| Hemolysis | 1 | 2001 | 174 | 0.040 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 4709 | 0.040 |
Why?
|
| Social Adjustment | 1 | 2009 | 56 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 227 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 1999 | 58 | 0.040 |
Why?
|
| Rifampin | 1 | 1999 | 69 | 0.040 |
Why?
|
| gamma-Globulins | 1 | 1998 | 19 | 0.040 |
Why?
|
| Steroid Hydroxylases | 1 | 1998 | 22 | 0.040 |
Why?
|
| Heart | 1 | 2003 | 631 | 0.040 |
Why?
|
| Pancreatin | 2 | 1991 | 5 | 0.040 |
Why?
|
| Colonoscopy | 2 | 2010 | 208 | 0.040 |
Why?
|
| Cephalometry | 1 | 2018 | 28 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1999 | 54 | 0.040 |
Why?
|
| Splenomegaly | 2 | 2012 | 17 | 0.040 |
Why?
|
| Gestational Age | 1 | 2021 | 765 | 0.040 |
Why?
|
| Genes | 1 | 1999 | 231 | 0.040 |
Why?
|
| Growth | 2 | 2004 | 58 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1998 | 112 | 0.040 |
Why?
|
| Ceruloplasmin | 2 | 1996 | 6 | 0.040 |
Why?
|
| Liver Glycogen | 1 | 1998 | 23 | 0.040 |
Why?
|
| Choledochal Cyst | 1 | 1998 | 20 | 0.040 |
Why?
|
| Succinic Acid | 1 | 1998 | 46 | 0.040 |
Why?
|
| Congenital Abnormalities | 1 | 1999 | 74 | 0.040 |
Why?
|
| Genes, Viral | 1 | 1998 | 93 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 1999 | 85 | 0.040 |
Why?
|
| Technetium Tc 99m Disofenin | 1 | 1998 | 3 | 0.040 |
Why?
|
| X Chromosome | 1 | 1998 | 47 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 1004 | 0.040 |
Why?
|
| Drug Antagonism | 1 | 1998 | 8 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 1096 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 755 | 0.040 |
Why?
|
| Glycosylation | 1 | 2018 | 129 | 0.040 |
Why?
|
| Glycogen Storage Disease | 1 | 1998 | 21 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 229 | 0.040 |
Why?
|
| Postoperative Period | 1 | 1999 | 309 | 0.040 |
Why?
|
| Phosphorylase Kinase | 1 | 1998 | 27 | 0.040 |
Why?
|
| Life Style | 1 | 2000 | 431 | 0.040 |
Why?
|
| Half-Life | 1 | 1998 | 147 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 90 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 1999 | 175 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2007 | 1006 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 89 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2001 | 6562 | 0.040 |
Why?
|
| RNA, Viral | 2 | 1998 | 572 | 0.040 |
Why?
|
| Gallbladder | 1 | 2017 | 15 | 0.040 |
Why?
|
| Caffeine | 1 | 1998 | 61 | 0.040 |
Why?
|
| Placebo Effect | 1 | 1997 | 52 | 0.040 |
Why?
|
| Glutathione Peroxidase | 1 | 1997 | 54 | 0.040 |
Why?
|
| Motor Skills | 1 | 2018 | 85 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1998 | 321 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 954 | 0.040 |
Why?
|
| Menkes Kinky Hair Syndrome | 1 | 1996 | 1 | 0.040 |
Why?
|
| Creatinine | 1 | 1999 | 491 | 0.040 |
Why?
|
| Point Mutation | 1 | 1998 | 228 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 147 | 0.040 |
Why?
|
| Hospital Costs | 1 | 1997 | 110 | 0.040 |
Why?
|
| Stereoisomerism | 2 | 1993 | 93 | 0.040 |
Why?
|
| Carrier Proteins | 3 | 1996 | 726 | 0.040 |
Why?
|
| Peripheral Nerves | 2 | 1987 | 65 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 1996 | 44 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 272 | 0.030 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 1996 | 11 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 456 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 462 | 0.030 |
Why?
|
| Duodenum | 1 | 1996 | 67 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2003 | 703 | 0.030 |
Why?
|
| Bacterial Translocation | 1 | 1996 | 36 | 0.030 |
Why?
|
| Mesentery | 1 | 1996 | 56 | 0.030 |
Why?
|
| Brain | 3 | 2018 | 2490 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 1996 | 88 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1285 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2015 | 27 | 0.030 |
Why?
|
| Cholic Acids | 1 | 1995 | 17 | 0.030 |
Why?
|
| Ligation | 2 | 1996 | 82 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2015 | 30 | 0.030 |
Why?
|
| Polyamines | 1 | 1996 | 39 | 0.030 |
Why?
|
| Lipid Peroxides | 1 | 1995 | 8 | 0.030 |
Why?
|
| Phagocytes | 1 | 1996 | 91 | 0.030 |
Why?
|
| Asphyxia | 1 | 1995 | 22 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 307 | 0.030 |
Why?
|
| Crigler-Najjar Syndrome | 1 | 1995 | 2 | 0.030 |
Why?
|
| Glycylglycine | 1 | 1995 | 2 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 1995 | 9 | 0.030 |
Why?
|
| Capsule Endoscopes | 1 | 2015 | 8 | 0.030 |
Why?
|
| Agglutinins | 1 | 1995 | 2 | 0.030 |
Why?
|
| Dietary Proteins | 2 | 1993 | 131 | 0.030 |
Why?
|
| Cryoglobulins | 1 | 1995 | 7 | 0.030 |
Why?
|
| Coombs Test | 1 | 1995 | 5 | 0.030 |
Why?
|
| Cryoglobulinemia | 1 | 1995 | 5 | 0.030 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 1996 | 87 | 0.030 |
Why?
|
| Disabled Persons | 1 | 1997 | 147 | 0.030 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 11 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1995 | 32 | 0.030 |
Why?
|
| Vitamin K Deficiency | 1 | 1994 | 10 | 0.030 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2015 | 32 | 0.030 |
Why?
|
| Cytokines | 3 | 2011 | 1900 | 0.030 |
Why?
|
| Aged | 4 | 2001 | 19661 | 0.030 |
Why?
|
| Ileum | 1 | 1995 | 100 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 1996 | 190 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 1995 | 23 | 0.030 |
Why?
|
| Calcium | 1 | 2001 | 1171 | 0.030 |
Why?
|
| Rats, Mutant Strains | 1 | 1994 | 25 | 0.030 |
Why?
|
| Permeability | 1 | 2015 | 156 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2014 | 38 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 202 | 0.030 |
Why?
|
| Hypobetalipoproteinemias | 2 | 1991 | 2 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 42 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2014 | 35 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 112 | 0.030 |
Why?
|
| Breath Tests | 1 | 2014 | 90 | 0.030 |
Why?
|
| Malondialdehyde | 2 | 1996 | 30 | 0.030 |
Why?
|
| Iron | 1 | 1996 | 248 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 1996 | 241 | 0.030 |
Why?
|
| Hyperbilirubinemia | 2 | 2005 | 16 | 0.030 |
Why?
|
| Length of Stay | 1 | 1998 | 1031 | 0.030 |
Why?
|
| Endoscopy | 1 | 1996 | 272 | 0.030 |
Why?
|
| Health Promotion | 1 | 2000 | 691 | 0.030 |
Why?
|
| Cimetidine | 1 | 1993 | 16 | 0.030 |
Why?
|
| Ranitidine | 1 | 1993 | 13 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 140 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 926 | 0.030 |
Why?
|
| Dogs | 1 | 1994 | 371 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2015 | 193 | 0.030 |
Why?
|
| Kidney | 3 | 1995 | 1357 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1785 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 1993 | 45 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1993 | 37 | 0.030 |
Why?
|
| Rectal Fistula | 1 | 2013 | 21 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2014 | 336 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1993 | 34 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 1996 | 455 | 0.030 |
Why?
|
| Diuretics | 1 | 1993 | 76 | 0.030 |
Why?
|
| Phototherapy | 1 | 1993 | 25 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 45 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 305 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 333 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 1991 | 57 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 1996 | 248 | 0.030 |
Why?
|
| Salmonella Infections | 1 | 1993 | 51 | 0.030 |
Why?
|
| Platelet Count | 1 | 2012 | 83 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2014 | 417 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 565 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 246 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 276 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1244 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 189 | 0.030 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2007 | 98 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1998 | 2073 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 204 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2012 | 305 | 0.030 |
Why?
|
| Absorption | 2 | 1990 | 56 | 0.030 |
Why?
|
| Documentation | 1 | 2013 | 175 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2011 | 7 | 0.030 |
Why?
|
| Trypsinogen | 1 | 1991 | 9 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2012 | 56 | 0.030 |
Why?
|
| Pancreatic Diseases | 1 | 1992 | 63 | 0.030 |
Why?
|
| Diffuse Cerebral Sclerosis of Schilder | 1 | 1991 | 4 | 0.030 |
Why?
|
| Diarrhea, Infantile | 1 | 1991 | 7 | 0.030 |
Why?
|
| Connective Tissue | 1 | 2011 | 37 | 0.030 |
Why?
|
| Vital Capacity | 1 | 2012 | 260 | 0.030 |
Why?
|
| Drug Overdose | 1 | 1996 | 294 | 0.030 |
Why?
|
| Electrolytes | 1 | 1991 | 59 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 1781 | 0.020 |
Why?
|
| Choledochostomy | 1 | 2011 | 7 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2012 | 114 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 21 | 0.020 |
Why?
|
| Blood Bactericidal Activity | 1 | 2010 | 37 | 0.020 |
Why?
|
| Uric Acid | 1 | 2014 | 354 | 0.020 |
Why?
|
| Coproporphyrins | 1 | 1990 | 3 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1990 | 7 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 452 | 0.020 |
Why?
|
| Porphyrins | 1 | 1990 | 17 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 1990 | 73 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 185 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 133 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2012 | 520 | 0.020 |
Why?
|
| Cognition | 1 | 2018 | 1025 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 410 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2010 | 56 | 0.020 |
Why?
|
| Asia | 1 | 1990 | 54 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 1992 | 574 | 0.020 |
Why?
|
| Emotions | 1 | 2015 | 495 | 0.020 |
Why?
|
| Hydroxycholecalciferols | 1 | 1989 | 3 | 0.020 |
Why?
|
| Africa | 1 | 1990 | 100 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1995 | 448 | 0.020 |
Why?
|
| Infant Nutrition Disorders | 1 | 1989 | 11 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 443 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1992 | 396 | 0.020 |
Why?
|
| Carrier State | 1 | 1990 | 57 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 1990 | 95 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 198 | 0.020 |
Why?
|
| Hemoglobin SC Disease | 1 | 1989 | 15 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 505 | 0.020 |
Why?
|
| Body Height | 1 | 1990 | 187 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 408 | 0.020 |
Why?
|
| Protozoan Infections | 1 | 1989 | 11 | 0.020 |
Why?
|
| Hyaline Membrane Disease | 1 | 1989 | 20 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 636 | 0.020 |
Why?
|
| Solubility | 1 | 1989 | 235 | 0.020 |
Why?
|
| Colitis | 1 | 1991 | 219 | 0.020 |
Why?
|
| Nervous System | 1 | 1989 | 66 | 0.020 |
Why?
|
| Mammalian orthoreovirus 3 | 1 | 1988 | 35 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 1523 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1195 | 0.020 |
Why?
|
| Monocytes | 1 | 2011 | 513 | 0.020 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 1989 | 50 | 0.020 |
Why?
|
| Digestive System | 1 | 1988 | 30 | 0.020 |
Why?
|
| Rectum | 2 | 1991 | 157 | 0.020 |
Why?
|
| Living Donors | 1 | 2011 | 319 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 812 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1992 | 1067 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 1989 | 64 | 0.020 |
Why?
|
| Hemophilia A | 1 | 1989 | 71 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 749 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 305 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1988 | 181 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1989 | 162 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2007 | 4 | 0.020 |
Why?
|
| Heart Failure | 1 | 2000 | 1968 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2007 | 26 | 0.020 |
Why?
|
| Micelles | 1 | 2007 | 34 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 415 | 0.020 |
Why?
|
| Oligoclonal Bands | 1 | 2007 | 20 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 224 | 0.020 |
Why?
|
| Biological Availability | 1 | 2007 | 126 | 0.020 |
Why?
|
| Myoclonus | 1 | 1987 | 11 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 2851 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 123 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 897 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2007 | 85 | 0.020 |
Why?
|
| Self Report | 1 | 2010 | 699 | 0.020 |
Why?
|
| Liver Extracts | 1 | 2006 | 1 | 0.020 |
Why?
|
| Chromans | 1 | 2006 | 20 | 0.020 |
Why?
|
| Kinetics | 2 | 2005 | 1625 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2006 | 93 | 0.020 |
Why?
|
| Propionates | 1 | 2006 | 35 | 0.020 |
Why?
|
| Triglycerides | 3 | 1996 | 521 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 842 | 0.020 |
Why?
|
| Pancreatic Extracts | 1 | 1985 | 2 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1985 | 4 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 204 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 1989 | 230 | 0.020 |
Why?
|
| Reflex, Abnormal | 1 | 1985 | 8 | 0.020 |
Why?
|
| Biliary Tract | 1 | 2005 | 17 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2005 | 21 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2006 | 333 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2014 | 1184 | 0.020 |
Why?
|
| Autopsy | 1 | 2005 | 90 | 0.020 |
Why?
|
| Muscles | 1 | 1987 | 333 | 0.020 |
Why?
|
| United Kingdom | 1 | 2006 | 236 | 0.020 |
Why?
|
| Neoplasms | 1 | 2009 | 2179 | 0.020 |
Why?
|
| Amylopectin | 1 | 2005 | 5 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2003 | 827 | 0.020 |
Why?
|
| Lipase | 1 | 1985 | 70 | 0.020 |
Why?
|
| Sputum | 1 | 2007 | 291 | 0.020 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2007 | 131 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2005 | 94 | 0.020 |
Why?
|
| Glycocholic Acid | 1 | 1985 | 6 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2006 | 230 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1987 | 227 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1989 | 710 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 1946 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2006 | 132 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 1984 | 10 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 165 | 0.020 |
Why?
|
| Nasal Septum | 1 | 1984 | 17 | 0.020 |
Why?
|
| Portal System | 1 | 2004 | 15 | 0.020 |
Why?
|
| Respiratory Mucosa | 1 | 2006 | 254 | 0.020 |
Why?
|
| Insulin | 1 | 2014 | 2170 | 0.020 |
Why?
|
| Nasopharynx | 1 | 1984 | 64 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2004 | 32 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 1984 | 82 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2006 | 327 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1991 | 718 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1984 | 222 | 0.010 |
Why?
|
| Neurologic Manifestations | 1 | 1983 | 3 | 0.010 |
Why?
|
| Reye Syndrome | 1 | 1983 | 4 | 0.010 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2003 | 24 | 0.010 |
Why?
|
| Autoantigens | 1 | 2006 | 397 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 2003 | 55 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1983 | 78 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1983 | 116 | 0.010 |
Why?
|
| Health | 1 | 2003 | 81 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 693 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1983 | 55 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2004 | 174 | 0.010 |
Why?
|
| Vomiting | 1 | 1983 | 123 | 0.010 |
Why?
|
| Biological Transport | 1 | 1983 | 382 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 2003 | 224 | 0.010 |
Why?
|
| Chickenpox | 1 | 1983 | 100 | 0.010 |
Why?
|
| Giardiasis | 1 | 1982 | 14 | 0.010 |
Why?
|
| Chylomicrons | 2 | 1993 | 7 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 1983 | 137 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 556 | 0.010 |
Why?
|
| Spine | 1 | 1983 | 144 | 0.010 |
Why?
|
| Succinate Cytochrome c Oxidoreductase | 1 | 2001 | 2 | 0.010 |
Why?
|
| NADH Dehydrogenase | 1 | 2001 | 18 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 61 | 0.010 |
Why?
|
| Fingers | 1 | 1982 | 83 | 0.010 |
Why?
|
| Citrate (si)-Synthase | 1 | 2001 | 49 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 374 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2006 | 1435 | 0.010 |
Why?
|
| Hand | 1 | 1982 | 137 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2000 | 165 | 0.010 |
Why?
|
| Face | 1 | 1982 | 165 | 0.010 |
Why?
|
| Erysipelas | 1 | 1980 | 1 | 0.010 |
Why?
|
| Ampicillin | 1 | 1980 | 13 | 0.010 |
Why?
|
| Physical Examination | 1 | 2002 | 243 | 0.010 |
Why?
|
| Methicillin | 1 | 1980 | 12 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 565 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1980 | 20 | 0.010 |
Why?
|
| Haemophilus influenzae | 1 | 1980 | 50 | 0.010 |
Why?
|
| Skin | 1 | 1984 | 657 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 963 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2001 | 361 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1983 | 331 | 0.010 |
Why?
|
| Cytochrome P450 Family 7 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1597 | 0.010 |
Why?
|
| CHO Cells | 1 | 1998 | 143 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 136 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 263 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 268 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1998 | 171 | 0.010 |
Why?
|
| Multigene Family | 1 | 1998 | 200 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2874 | 0.010 |
Why?
|
| Esophagoscopes | 1 | 1996 | 5 | 0.010 |
Why?
|
| Comorbidity | 1 | 2002 | 1527 | 0.010 |
Why?
|
| Apolipoprotein B-100 | 1 | 1996 | 8 | 0.010 |
Why?
|
| Autoradiography | 1 | 1996 | 72 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1996 | 34 | 0.010 |
Why?
|
| Microsomes | 1 | 1996 | 24 | 0.010 |
Why?
|
| Endoscopes | 1 | 1996 | 19 | 0.010 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 1996 | 17 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1996 | 269 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 1995 | 20 | 0.010 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1995 | 24 | 0.010 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1995 | 31 | 0.010 |
Why?
|
| Ulcer | 1 | 1995 | 28 | 0.010 |
Why?
|
| Sicily | 1 | 1995 | 1 | 0.010 |
Why?
|
| Africa, Northern | 1 | 1995 | 4 | 0.010 |
Why?
|
| Genomic Library | 1 | 1995 | 14 | 0.010 |
Why?
|
| France | 1 | 1995 | 35 | 0.010 |
Why?
|
| Denmark | 1 | 1995 | 41 | 0.010 |
Why?
|
| England | 1 | 1995 | 68 | 0.010 |
Why?
|
| Hypoglycemia | 1 | 1999 | 401 | 0.010 |
Why?
|
| Germany | 1 | 1995 | 89 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1995 | 100 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1995 | 219 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 372 | 0.010 |
Why?
|
| Diarrhea | 1 | 1995 | 181 | 0.010 |
Why?
|
| Fever | 1 | 1995 | 283 | 0.010 |
Why?
|
| Epitopes | 1 | 1996 | 443 | 0.010 |
Why?
|
| Exons | 1 | 1995 | 308 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1995 | 297 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 533 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 510 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1998 | 442 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 1993 | 20 | 0.010 |
Why?
|
| Acetaminophen | 1 | 1995 | 244 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1993 | 82 | 0.010 |
Why?
|
| Deuterium | 1 | 1993 | 78 | 0.010 |
Why?
|
| Sheep | 1 | 1995 | 764 | 0.010 |
Why?
|
| Transfection | 1 | 1995 | 890 | 0.010 |
Why?
|
| Recurrence | 1 | 1995 | 975 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 1993 | 138 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1992 | 59 | 0.010 |
Why?
|
| Synapses | 1 | 1995 | 344 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 67 | 0.010 |
Why?
|
| Sweat | 1 | 1991 | 38 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1991 | 70 | 0.010 |
Why?
|
| Sulfasalazine | 1 | 1991 | 21 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1991 | 81 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1991 | 115 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 1991 | 50 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1991 | 67 | 0.010 |
Why?
|
| Status Epilepticus | 1 | 1991 | 36 | 0.010 |
Why?
|
| Isomerism | 1 | 1990 | 43 | 0.010 |
Why?
|
| Heterozygote | 1 | 1991 | 262 | 0.010 |
Why?
|
| Colorimetry | 1 | 1990 | 14 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1991 | 546 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1991 | 238 | 0.010 |
Why?
|
| Respiration | 1 | 1991 | 184 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1991 | 243 | 0.010 |
Why?
|
| Energy Intake | 1 | 1992 | 448 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1991 | 526 | 0.010 |
Why?
|
| Birth Weight | 1 | 1992 | 465 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1989 | 44 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 1323 | 0.010 |
Why?
|
| Breast Feeding | 1 | 1992 | 386 | 0.010 |
Why?
|
| Phospholipids | 1 | 1990 | 208 | 0.010 |
Why?
|
| Alleles | 1 | 1991 | 832 | 0.010 |
Why?
|
| Fats | 1 | 1987 | 13 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1987 | 606 | 0.000 |
Why?
|